Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice

Human prostate cancer frequently metastasizes to bone, where it gives rise to osteoblastic bone metastases with an underlying osteoclastic component and subsequent bone pain. However, the importance of osteoclastogenesis in the development of prostate cancer bone lesions in humans is unclear. Osteop...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2003-05, Vol.63 (9), p.2096-2102
Hauptverfasser:	YONOU, Hiroyuki, KANOMATA, Naoki, GOYA, Masato, KAMIJO, Tomoyuki, YOKOSE, Tomoyuki, HASEBE, Takahiro, NAGAI, Kanji, HATANO, Tadashi, OGAWA, Yoshihide, OCHIAI, Atsushi
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Biological and medical sciences Bone Neoplasms - drug therapy Bone Neoplasms - prevention & control Bone Neoplasms - secondary Cell Division - drug effects Chemotherapy Glycoproteins - pharmacology Humans Male Medical sciences Mice Mice, Inbred NOD Mice, SCID Osteoprotegerin Pharmacology. Drug treatments Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Receptors, Cytoplasmic and Nuclear Receptors, Tumor Necrosis Factor Recombinant Proteins - pharmacology Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!